David Lee Johnson Global Blood Therapeutics, Inc. (GBT) insider trading activity

David Lee Johnson is Chief Commercial Officer of Global Blood Therapeutics, Inc.. Currently has a direct ownership of 0 shares of GBT, which is worth approximately $0. The most recent transaction as insider was on Oct 05, 2022, when has been sold 34,384 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

DAVID LEE JOHNSON Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 05 2022	SELL Sale (or disposition) back to the issuer	-	34,384 Reduced 100.0%	0 Common Stock
Sep 28 2022	SELL Bona fide gift	-	22,000 Reduced 39.02%	34,384 Common Stock
Sep 01 2022	SELL Payment of exercise price or tax liability	$143,319 $68.15 p/Share	2,103 Reduced 3.6%	56,384 Common Stock
Sep 01 2022	BUY Exercise of conversion of derivative security	-	4,971 Added 7.83%	58,487 Common Stock
Aug 31 2022	BUY Grant, award, or other acquisition	$9,260 $25.37 p/Share	365 Added 0.68%	53,516 Common Stock
Aug 01 2022	SELL Payment of exercise price or tax liability	$75,881 $32.4 p/Share	2,342 Reduced 4.22%	53,151 Common Stock
Aug 01 2022	BUY Exercise of conversion of derivative security	-	6,770 Added 10.87%	55,493 Common Stock

Apr 01 2022	SELL Payment of exercise price or tax liability	$54,332 $35.91 p/Share	1,513 Reduced 3.03%	48,424 Common Stock
Apr 01 2022	BUY Exercise of conversion of derivative security	-	4,375 Added 8.06%	49,937 Common Stock
Mar 01 2022	SELL Payment of exercise price or tax liability	$28,556 $29.87 p/Share	956 Reduced 2.06%	45,562 Common Stock
Mar 01 2022	BUY Exercise of conversion of derivative security	-	2,763 Added 5.61%	46,518 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	$11,975 $25.37 p/Share	472 Added 1.07%	43,755 Common Stock
Feb 01 2022	SELL Payment of exercise price or tax liability	$75,055 $29.33 p/Share	2,559 Reduced 5.58%	43,283 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	-	6,770 Added 12.87%	45,842 Common Stock
Oct 01 2021	SELL Payment of exercise price or tax liability	$56,962 $26.25 p/Share	2,170 Reduced 5.26%	39,072 Common Stock
Oct 01 2021	BUY Exercise of conversion of derivative security	-	4,375 Added 9.59%	41,242 Common Stock
Sep 01 2021	SELL Payment of exercise price or tax liability	$31,999 $29.85 p/Share	1,072 Reduced 2.83%	36,867 Common Stock
Sep 01 2021	BUY Exercise of conversion of derivative security	-	2,762 Added 6.79%	37,939 Common Stock
Aug 31 2021	BUY Grant, award, or other acquisition	$11,707 $24.39 p/Share	480 Added 1.35%	35,177 Common Stock
Aug 01 2021	SELL Payment of exercise price or tax liability	$64,007 $27.33 p/Share	2,342 Reduced 6.32%	34,697 Common Stock
Aug 01 2021	BUY Exercise of conversion of derivative security	-	6,770 Added 15.45%	37,039 Common Stock
Apr 01 2021	SELL Payment of exercise price or tax liability	$64,484 $42.62 p/Share	1,513 Reduced 4.76%	30,269 Common Stock
Apr 01 2021	BUY Exercise of conversion of derivative security	-	4,375 Added 12.1%	31,782 Common Stock
Feb 28 2021	BUY Grant, award, or other acquisition	$13,579 $36.21 p/Share	375 Added 1.35%	27,407 Common Stock
Feb 01 2021	SELL Payment of exercise price or tax liability	$121,646 $49.49 p/Share	2,458 Reduced 8.34%	27,032 Common Stock

Also insider at

CRBU

Caribou Biosciences, Inc. Healthcare

Director

VERA

Vera Therapeutics, Inc. Healthcare

Chief Operating Officer

DLJ